US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
China Takes 5th Consecutive Women's Team Title in Asiad Table Tennis
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Closing Ceremony of 31st FISU Summer World University Games Held in Chengdu
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Beijing Registers over 300 Medical Social Workers
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
A 19-year-old British tourist who was subjected to a horrific sex attack in Majorca 'was gang-raped2024-05-21NW China's Zhaosu County Enters Peak Tourism Season in Summer
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment